JP7822953B2 - 急性骨髄性白血病（ａｍｌ）に対する新規の腫瘍特異的抗原及びそれらの使用 - Google Patents

急性骨髄性白血病（ａｍｌ）に対する新規の腫瘍特異的抗原及びそれらの使用

Info

Publication number
JP7822953B2
JP7822953B2 JP2022562561A JP2022562561A JP7822953B2 JP 7822953 B2 JP7822953 B2 JP 7822953B2 JP 2022562561 A JP2022562561 A JP 2022562561A JP 2022562561 A JP2022562561 A JP 2022562561A JP 7822953 B2 JP7822953 B2 JP 7822953B2
Authority
JP
Japan
Prior art keywords
seq
hla
aml
tap
tsa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022562561A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023521219A (ja
JP2023521219A5 (enExample
Inventor
ペロー クラウデ
ティボー ピエール
ルミュー セバスティアン
エークス グレゴリー
ハーディ マリー－ピエール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Montreal
Original Assignee
University of Montreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Montreal filed Critical University of Montreal
Publication of JP2023521219A publication Critical patent/JP2023521219A/ja
Publication of JP2023521219A5 publication Critical patent/JP2023521219A5/ja
Priority to JP2025153952A priority Critical patent/JP2026009916A/ja
Application granted granted Critical
Publication of JP7822953B2 publication Critical patent/JP7822953B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022562561A 2020-04-14 2021-03-15 急性骨髄性白血病（ａｍｌ）に対する新規の腫瘍特異的抗原及びそれらの使用 Active JP7822953B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025153952A JP2026009916A (ja) 2020-04-14 2025-09-17 急性骨髄性白血病（ａｍｌ）に対する新規の腫瘍特異的抗原及びそれらの使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063009853P 2020-04-14 2020-04-14
US63/009,853 2020-04-14
PCT/CA2021/050340 WO2021207823A1 (en) 2020-04-14 2021-03-15 Novel tumor-specific antigens for acute myeloid leukemia (aml) and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025153952A Division JP2026009916A (ja) 2020-04-14 2025-09-17 急性骨髄性白血病（ａｍｌ）に対する新規の腫瘍特異的抗原及びそれらの使用

Publications (3)

Publication Number Publication Date
JP2023521219A JP2023521219A (ja) 2023-05-23
JP2023521219A5 JP2023521219A5 (enExample) 2024-02-29
JP7822953B2 true JP7822953B2 (ja) 2026-03-03

Family

ID=78083452

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022562561A Active JP7822953B2 (ja) 2020-04-14 2021-03-15 急性骨髄性白血病（ａｍｌ）に対する新規の腫瘍特異的抗原及びそれらの使用
JP2025153952A Pending JP2026009916A (ja) 2020-04-14 2025-09-17 急性骨髄性白血病（ａｍｌ）に対する新規の腫瘍特異的抗原及びそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025153952A Pending JP2026009916A (ja) 2020-04-14 2025-09-17 急性骨髄性白血病（ａｍｌ）に対する新規の腫瘍特異的抗原及びそれらの使用

Country Status (11)

Country Link
US (1) US20230287070A1 (enExample)
EP (1) EP4136099A4 (enExample)
JP (2) JP7822953B2 (enExample)
KR (1) KR20220167288A (enExample)
CN (1) CN115397842A (enExample)
AU (1) AU2021256477A1 (enExample)
BR (1) BR112022020376A2 (enExample)
CA (1) CA3173666A1 (enExample)
IL (1) IL296881A (enExample)
MX (1) MX2022012758A (enExample)
WO (1) WO2021207823A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026009916A (ja) * 2020-04-14 2026-01-21 ウニヴェルシテ ド モントリオール 急性骨髄性白血病（ａｍｌ）に対する新規の腫瘍特異的抗原及びそれらの使用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114045341B (zh) * 2021-11-30 2024-03-01 中南大学 口腔黏膜下纤维化恶性进展或其所致口腔癌的早期诊断和/或预后生物标志物的应用及产品
US20240013860A1 (en) * 2022-07-06 2024-01-11 Bioinformatics Solutions Inc. Methods and systems for personalized neoantigen prediction
EP4602051A1 (en) * 2022-10-11 2025-08-20 Université de Montréal Novel tumor-specific antigens for myeloid leukemia and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017524337A (ja) 2014-05-09 2017-08-31 イマティクス バイオテクノロジーズ ゲーエムベーハー 急性骨髄性白血病（ａｍｌ）などの血液のいくつかの腫瘍に対する新規免疫療法
JP2018520670A (ja) 2015-06-24 2018-08-02 アイム・セラピューティクス・べー・フェー Ａｍｌ抗原及びその使用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867283B2 (en) * 2001-05-16 2005-03-15 Technion Research & Development Foundation Ltd. Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells
PT2119726E (pt) * 2008-05-14 2015-03-30 Immatics Biotechnologies Gmbh Novos e poderosos peptídeos para mhc classe ii derivados de survinina e neurocano
EP2576614A4 (en) * 2010-05-24 2013-11-13 Phosimmune Inc CLASS I-MHC PHOSPHOPEPTIDES FOR CANCER IMMUNOTHERAPY AND DIAGNOSIS
WO2014157692A1 (ja) * 2013-03-29 2014-10-02 大日本住友製薬株式会社 Ｗｔ１抗原ペプチドコンジュゲートワクチン
HRP20191671T1 (hr) * 2014-05-09 2019-12-13 Immatics Biotechnologies Gmbh Nova imunoterapija za liječenje nekoliko tumora krvi, kao što je akutna mijeloidna leukemija (aml)
HRP20200967T1 (hr) * 2014-06-20 2020-10-16 Immatics Biotechnologies Gmbh Nova imunoterapija protiv nekoliko tumora krvi, posebice kronične limfoidne leukemije (cll)
GB201411037D0 (en) * 2014-06-20 2014-08-06 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL)
EP3277841A1 (en) * 2015-03-31 2018-02-07 INSERM (Institut National de la Santé et de la Recherche Médicale) New biomarker for outcome in aml
GB201511546D0 (en) * 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
GB201513921D0 (en) * 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
SG10202110335PA (en) * 2016-04-06 2021-10-28 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against aml and other cancers
TW202304970A (zh) * 2016-08-26 2023-02-01 德商英麥提克生物技術股份有限公司 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架
TW201841937A (zh) * 2017-04-10 2018-12-01 德商英麥提克生物技術股份有限公司 用於白血病和其他癌症免疫治療的新穎肽和肽組合物
US10925947B2 (en) * 2018-06-29 2021-02-23 Immatics Biotechnologies Gmbh A*03 restricted peptides for use in immunotherapy against cancers and related methods
TW202019955A (zh) * 2018-07-31 2020-06-01 德商英麥提克生物技術股份有限公司 B*07 限制肽和肽組合的抗癌免疫治療和相關方法
MX2021002333A (es) * 2018-08-30 2021-04-28 Univ Montreal Metodo basado en proteogenomica para identificar antigenos especificos de tumores.
TW202024121A (zh) * 2018-09-18 2020-07-01 德商英麥提克生物技術股份有限公司 A*01 限制肽和肽組合物在抗癌免疫治療中的用途和相關方法
JP7822953B2 (ja) * 2020-04-14 2026-03-03 ウニヴェルシテ ド モントリオール 急性骨髄性白血病（ａｍｌ）に対する新規の腫瘍特異的抗原及びそれらの使用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017524337A (ja) 2014-05-09 2017-08-31 イマティクス バイオテクノロジーズ ゲーエムベーハー 急性骨髄性白血病（ａｍｌ）などの血液のいくつかの腫瘍に対する新規免疫療法
JP2018520670A (ja) 2015-06-24 2018-08-02 アイム・セラピューティクス・べー・フェー Ａｍｌ抗原及びその使用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Curr. Drug Targets，2017年，Vol.18, No.3，pp.296-303 (Author manuscript pp.1-16)
Front. Immunol.，2019年，Vol.10, No.2934，pp.1-7
Genome Medicine，2019年，Vol.11, No.29，pp.1-3

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026009916A (ja) * 2020-04-14 2026-01-21 ウニヴェルシテ ド モントリオール 急性骨髄性白血病（ａｍｌ）に対する新規の腫瘍特異的抗原及びそれらの使用

Also Published As

Publication number Publication date
US20230287070A1 (en) 2023-09-14
JP2023521219A (ja) 2023-05-23
MX2022012758A (es) 2022-11-30
IL296881A (en) 2022-12-01
CA3173666A1 (en) 2021-10-21
BR112022020376A2 (pt) 2022-11-22
CN115397842A (zh) 2022-11-25
JP2026009916A (ja) 2026-01-21
AU2021256477A1 (en) 2022-11-10
EP4136099A1 (en) 2023-02-22
EP4136099A4 (en) 2024-08-07
KR20220167288A (ko) 2022-12-20
WO2021207823A1 (en) 2021-10-21

Similar Documents

Publication Publication Date Title
Ehx et al. Atypical acute myeloid leukemia-specific transcripts generate shared and immunogenic MHC class-I-associated epitopes
US20230242583A1 (en) Proteogenomic-based method for identifying tumor-specific antigens
US20230287070A1 (en) Novel tumor-specific antigens for acute myeloid leukemia (aml) and uses thereof
US20250136937A1 (en) Novel tumor-specific antigens for colorectal cancer and uses thereof
IL323881A (en) Novel tumor antigens for melanoma and uses thereof
WO2025097243A1 (en) Colorectal tumor antigens and uses thereof
US20260048105A1 (en) Novel antigens for cancer and uses thereof
US20240382590A1 (en) Novel tumor-specific antigens for cancer stem cells and uses thereof
HK40015695A (en) Novel immunotherapy against several tumors, such as lung cancer including nsclc

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250423

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250520

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250929

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251224

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260120

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260218

R150 Certificate of patent or registration of utility model

Ref document number: 7822953

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150